國家級人體生物資料庫整合平台共同資料模式實作指引(NBCT Common Data Model IG)
1.1.0 - Release1.1.0
國家級人體生物資料庫整合平台共同資料模式實作指引(NBCT Common Data Model IG)
1.1.0 - Release1.1.0
This page is part of the 國家級人體生物資料庫整合平台共同資料模式實作指引(NBCT Common Data Model IG) (v1.1.0: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
| Official URL: https://www.ghd.tw/cdm-fhir/ValueSet/ssf-2-leukemia-valueset-vs | Version: 1.1.0 | |||
| Active as of 2024-08-01 | Computable Name: SSF2leukemiaVS | |||
Assessment of molecular studies in leukemia Value Set
References
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs version 📦1.1.0
Expansion performed internally based on codesystem SSF2 白血病-白血病分子生物學檢查的評估代碼系統 v1.1.0 (CodeSystem)
This value set contains 33 concepts
| System | Code | Display (zh) | JSON | XML |
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 000 | 正常 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 001 | AML with RUNX1-RUNX1T1 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 002 | AML with CBFB-MYH11 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 003 | Acute promyelocytic leukemia with PML-RARA | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 004 | AML with KMT2A-MLLT3 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 005 | AML with DEK-NUP214 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 006 | AML with GATA2, MECOM | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 007 | AML(megakaryoblastic) with RBM15-MKL1 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 008 | AML with mutated NPM1 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 009 | AML with biallelic mutation of CEBPA | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 010 | AML with mutated FLT3/ITD | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 011 | AML with mutated FLT3/TKD | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 012 | AML with MLL-PTD (partial tandem duplication) | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 013 | AML with BCR-ABL1 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 021 | B lymphoblastic leukemia/lymphoma with BCR-ABL1 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 022 | B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 023 | B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1) | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 024 | B-lymphoblastic leukemia/lymphoma with IGH/IL3 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 025 | B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1) | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 041 | Mixed phenotype acute leukemia with BCR-ABL1 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 042 | Mixed-phenotype acute leukemia with KMT2A-rearranged | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 051 | Chronic myelogenous leukemia BCR-ABL1 positive | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 052 | JAK2 V617F mutation | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 053 | Myeloid and lymphoid neoplasms with PDGFRA rearrangement | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 054 | Myeloid and lymphoid neoplasms with PDGFRB rearrangement | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 055 | Myeloid and lymphoid neoplasms with FGFR1 rearrangement | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 090 | (1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 091 | 同時有兩種(含)以上上述之分子檢驗異常 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 092 | 同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 8XX | Molecular study after chemotherapy or immunotherapy or target therapy | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 988 | 不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4) | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 998 | 有執行分子生物學檢查，但結果無法判斷 | ||
https://www.ghd.tw/cdm-fhir/CodeSystem/ssf-2-leukemia-codesystem-cs | 999 | (1) 病歷未記載或不詳 (2) 未執行分子生物學檢查 |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |